Pharmaceutical technology solubility enhancement of a poorly water-soluble anti-malarial drug: Experimental design and use of a modified multifluid nozzle pilot spray drier

Journal of Pharmaceutical Sciences

Volumn 98, Issue 1, 2009, Pages 281-296

  Sahoo, Nanda Gopal ^a   Abbas, Ali ^a   Judeh, Zaher ^a   Li, Chang Ming ^a   Yuen, Kah Hay ^b  

^a Nanyang Technological University   (Singapore)

^b SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

Author keywords

Artemisinin; Crystallinity; FTIR; Maltodextrin; Microparticles; Particle size; Solubility; Spray drying; Thermal analysis; X ray diffractometry

Indexed keywords

ARTEMISININ; MALTODEXTRIN; ANTIMALARIAL AGENT; WATER;

ARTICLE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; FLOW RATE; INFRARED SPECTROSCOPY; PARTICLE SIZE; PRESSURE; SCANNING ELECTRON MICROSCOPY; SPRAY DRYING; TEMPERATURE; THERMAL ANALYSIS; X RAY DIFFRACTION; CHEMISTRY; INSTRUMENTATION; METHODOLOGY; PILOT STUDY; SOLUBILITY;

ANTIMALARIALS; CHEMISTRY, PHARMACEUTICAL; PILOT PROJECTS; RESEARCH DESIGN; SOLUBILITY; WATER;

EID: 58149247922     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21399     Document Type: Article

References (32)

1. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46:3-26.
2. Subramaniam B, Rajewski RA, Snavely K. 1997. Pharmaceutical processing with supercritical carbon dioxide. J Pharm Sci 86:885-890.
3. Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86:1-12.
4. Grau MJ, Kayser O, Muller RH. 2000. Nanosuspensions of poorly soluble drugs-reproducibility of small scale production. Int J Pharm 196:155- 157.
5. Merisko-Liverside E, Liversidge GG, Cooper ER. 2003. Nonosizing: A formulation approach for poorly-water soluble compounds. Eur J Pharm Sci 18:113-120.
6. Rasenack N, Hartenhauer H, Muller BW. 2003. Microcrystals for dissolution rate enhancement of poorly water-soluble drugs. Int J Pharm 254:137- 145.
7. Rogers TL, Overhoff KA, Shah P, Santiago P, Yaca-man MJ, Johnson KP, William RO III, 2003. Micronized powders of a poorly water soluble drug produced by a spray-freezing into liquid-emulsion process. Eur J Pharm Biopharm 55:161-172.
8. Rogers TL, Hu J, Yu Z, Johnston KP, Williams RO. 2002. A novel particle engineering technology: Spray-freezing into liquid. Int J Pharm 242:93-100.
9. Hu J, Rogers TL, Brown JN, Young TJ, Johnston KP, Williams RO. 2002. Improvement of dissolution rates of poorly water soluble APIs using the novel spray freezing into liquid technology. Pharm Res 19:1278-1284.
10. Billon A, Bataille B, Cassanas G, Jacob M. 2000. Development of spray-dried acetaminophen micro-particles using experimental designs. Int J Pharm 203:159-168.
11. Moretti MDL, Gavini E, Juliano C, Pirisino G, Giunchedi P. 2001. Spray-dried microspheres con-taining ketoprofen formulated into capsules and tablets. J Microencapsul 18:111-121.
12. Dollo G, Le Corre P, Guerin A, Chevanne F, Burgot JL, Leverge R. 2004. Spray-dried redispersible oil-in-water emulsion to improve oral bioavailability of poorly soluble drugs. Eur J Pharm Biopharm 19: 273-280.
13. Jung J, Perrut M. 2001. Particle design using supercritical fluids: Literature and patent survey. J Super Fluids 20:179-219.
14. Shariati A, Peters CJ. 2003. Recent developments in particle design using supercritical fluids. Curr Opin Sol St Mater Sci 7:371-383.
15. Muhrer G, Meier U, Fusaro F, Albano S, Mazzotti M. 2006. Use of compressed gas precipitation to enhance the dissolution behavior of a poorly water soluble drug: Generation of drug microparticles and drug-polymer dispersions. Int J Pharm 308:69-83.
16. Augustijns P, D'Hulst A, Daele JV, Kinget R. 1996. Transport of artemisinin and sodium arsenate in caco-2 intestinal epithelial cells. J Pharm Sci 85: 577-579.
17. Barradell LB, Fitton A. 1995. Artesunate. A review of its pharmacology and therapeutic efficacy in the treatment of malaria. Drugs 50:714-741.
18. Titulaer HAC, Zuidema J, Lugt CB. 1991. Formulation and pharmacokinetics of artheinisinin and its derivatives. Int J Pharm 69:83-92.
19. Wong JW, Yuen KH. 2001. Improved oral bioavailability of artemisinin through inclusion complexation with β-, and γ-cyclodextrins. Int J Pharm 227:177-185.
20. Wong JW, Yuen KH. 2003. Inclusion complexation of artemisinin with α-, β-, and γ-cyclodextrins. Drug Dev Ind Pharm 29:1035-1044.
21. Beppu B, Ozeki, Sasaki Y, Mizoe T, Takashima Y, Yuasa H, Okada H. 2003. Preparation of particles for dry powder inhalation using a novel 4-fluid nozzle spray drier. J Pharm Sci Technol Jpn 63: 228-237.
22. Zhao SS. 1987. High-performance liquid chromatographic determination of artemisinin (qinghaosu) in human plasma and saliva. Analyst 112:661- 664.
23. Hsu CC, Wu SS, Walsh AJ. 1996. The preparation of recombinant human deoxyribonuclease powder: Comparative studies of spray drying versus lyophilization and application of microwave drying. Proceedings from the 10th International Drying Symposium (IDS'96), Vol. B, pp 1229-1236.
24. Stahl K, Claesson M, Lilliehorn P, Linden H, Backstrom K. 2002. The effect of process variables on the degradation and physical properties of spray dried insulin intended for inhalation. Int J Pharm 233: 227-237.
25. Broadhead J, Rouan SKE, Hau I, Rhodes CT. 1994. The effect of process and formulation variables on the properties of spray dried β-galaetosidase. J Pharm Pharmacol 46:458-467.
26. Ozeki T, Beppu S, Mizoe T, Takashima Y, Yuasa H, Okada H. 2005. Preparation of two-drug composite microparticles to improve the dissolution of insoluble drug in water for use with a 4-fluid nozzle spray drier. J Control Release 107:387-394.
27. Jindasa S. 1997. Analysis and production of artemisinin, and antimalarial from Artemisia annua L. Ph.D. Thesis, University of Science: Malaysia.
28. Noyes AA, Whitney WR. 1897. The rate of solution of solid substances in their own solutions. J Am Chem Soc 19:930-934.
29. M̈uller RH, Jacobs C, Kayser O. 2001. Nanosuspensions as particulate drug formulations in therapy rationale for development and what we can expect for the future. Adv Drug Deliv Rev 47:3-19.
30. Hancock BC, Zografi G. 1997. Characteristic and significance of the amorphous state in pharmaceutical systems. J Pharm Sci 86:1-12.
31. Valizadeh H, Nokhodchi A, Qarakhani N, Zakeri-Milani P, Azarmi S, Hassanzadeh D, Lobenberg R. 2004. Physicochemical characterization of solid dispersions of indomethacin with PEG 6000, Myrj 52, lactose, sorbitol, dextrin, and eudragit® E100. Drug Dev Ind Pharm 30:303-317.
32. Anhydro A/S. 2004. PSD 52 operating manual, Anhydro A/S, Soeborg, Denmark.